 <h1>Clarithromycin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of clarithromycin include:</b> dysgeusia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to clarithromycin: oral powder for suspension, oral tablet, oral tablet extended release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, clarithromycin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking clarithromycin:</p><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>fever</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Fever with or without chills</li>
<li>itching, skin rash</li>
<li>nausea</li>
<li>severe stomach cramps and pain</li>
<li>stomach tenderness</li>
<li>unusual bleeding or bruising</li>
<li>vomiting</li>
<li>watery and severe diarrhea, which may also be bloody</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>black, tarry stools</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>blurred vision</li>
<li>chest pain or discomfort</li>
<li>clay-colored stools</li>
<li>confusion about identity, place, and time</li>
<li>cool, pale skin</li>
<li>dark urine</li>
<li>depression</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fainting</li>
<li>fast, slow, pounding, or irregular heartbeat or pulse</li>
<li>feeling of unreality</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>hives</li>
<li>increased hunger</li>
<li>joint or muscle pain</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>nightmares</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>recurrent fainting</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>redness, swelling, or soreness of the tongue</li>
<li>seizures</li>
<li>sense of detachment from self or body</li>
<li>severe mood or mental changes</li>
<li>shakiness</li>
<li>skin eruptions</li>
<li>slurred speech</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach pain</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>unpleasant breath odor</li>
<li>unusual behavior</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of clarithromycin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Belching</li>
<li>bloated or full feeling</li>
<li>change in sensation of taste</li>
<li>excess air or gas in the stomach or bowels</li>
<li>headache</li>
<li>heartburn</li>
<li>indigestion</li>
<li>mild diarrhea</li>
<li>passing gas</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Change in sense of smell</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>feeling of constant movement of self or surroundings</li>
<li>hearing loss</li>
<li>lightheadedness</li>
<li>loss of taste</li>
<li>mood or mental changes</li>
<li>sensation of spinning</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>sore mouth or tongue</li>
<li>swelling or inflammation of the mouth</li>
<li>tongue discoloration</li>
<li>tooth discoloration</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<!-- end oral powder for suspension, oral tablet, oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to clarithromycin: oral powder for reconstitution, oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most common side effects were abdominal pain/discomfort, diarrhea, nausea, vomiting, and dysgeusia/taste perversion.</p>
<p></p>
<p>In immunocompromised patients treated with higher doses of this drug (1 to 2 g/day), the most common side effects were nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, increased AST, and increased ALT.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia/taste perversion (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Headache, dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Loss of consciousness, dyskinesia, somnolence, hearing impaired, tinnitus, tremor, vertigo</p>
<p><b>Frequency not reported</b>: New onset of symptoms of myasthenic syndrome, exacerbation of symptoms of myasthenia gravis, hearing disturbance, muzziness</p>
<p><b>Postmarketing reports</b>: Convulsions, ageusia, parosmia/smell perversion, anosmia, paresthesia, deafness, hyperkinesia<sup>[Ref]</sup></p><p>Deafness was reported mainly in elderly women and was usually reversible.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>The incidence of dry mouth was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.</p>
<p></p>
<p>Severity of pseudomembranous colitis has ranged from mild to life-threatening.</p>
<p></p>
<p>Tooth discoloration was usually reversible with professional dental cleaning after the drug was stopped.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 12.3%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea, vomiting, abdominal pain/discomfort, dyspepsia/heartburn, flatulence, oral candidiasis/moniliasis, constipation</p>
<p><b>Uncommon</b> (0.1% to 1%): Glossitis, stomatitis, esophagitis, gastroesophageal reflux disease, gastritis, proctalgia, abdominal distension, dry mouth, eructation, gastroenteritis, gastrointestinal hemorrhage, bleeding gums, bloodstained stools</p>
<p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis), pancreatitis</p>
<p><b>Postmarketing reports</b>: Acute pancreatitis, tongue discoloration, tooth discoloration, pseudomembranous colitis, enteritis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site phlebitis</p>
<p><b>Common</b> (1% to 10%): Injection site pain, injection site inflammation, tenderness at site of administration</p>
<p><b>Frequency not reported</b>: Vessel puncture site pain</p><p>These side effects are specific to the IV formulation.</p><h3>Hepatic</h3><p>Elevated AST (greater than 5 times the upper limit of normal [5 x ULN]) and ALT (greater than 5 x ULN) were reported in up to 4% and up to 3% of patients, respectively.</p>
<p></p>
<p>Hepatic dysfunction (sometimes severe and usually reversible), including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice have been reported.  In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases (e.g., preexisting liver disease) and/or concomitant medications (e.g., hepatotoxic agents).</p>
<p></p>
<p>Drug-induced hepatotoxicity was rare and typically associated with higher doses (1 to 2 g/day) and high serum drug levels.  The enzyme elevation pattern was usually cholestatic with minimal elevations of AST and ALT.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT, abnormal liver function test</p>
<p><b>Uncommon</b> (0.1% to 1%): Cholestasis, hepatitis (symptoms included anorexia, jaundice, dark urine, pruritus, tender abdomen), increased blood bilirubin, elevated GGT, elevated direct bilirubin, hepatic dysfunction (including increased liver enzymes), hepatitis and cholestasis with or without jaundice</p>
<p><b>Frequency not reported</b>: Hepatocellular and/or cholestatic hepatitis (with or without jaundice), drug-induced hepatotoxicity, fulminant hepatic failure</p>
<p><b>Postmarketing reports</b>: Hepatic failure, hepatocellular jaundice, adverse reactions related to hepatic dysfunction, abnormal hepatic function, liver abnormalities<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactoid reaction</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity, allergic reactions</p>
<p><b>Postmarketing reports</b>: Anaphylactic reaction, angioedema<sup>[Ref]</sup></p><p>Allergic reactions have ranged from urticaria and mild skin eruptions to rare cases of anaphylaxis.</p>
<p></p>
<p>A 92-year-old female admitted for heart failure and a right upper lobe infiltrate was started on clarithromycin 500 mg.  The following day, this drug was discontinued and IV antibiotics were initiated due to persisting fever.  She received only 1 dose of this drug.  On day 6 of the hospitalization, the patient was afebrile, IV antibiotics were stopped, and this drug was again started.  Two hours after the dose, the patient developed swelling in her lips, jaw, tongue, mouth, and face.  The patient was given diphenhydramine and the clarithromycin was discontinued.  She was discharged the following day.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Vasodilation, phlebitis</p>
<p><b>Uncommon</b> (0.1% to 1%): ECG QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations</p>
<p><b>Rare</b> (0.01% to 0.1%): Arrhythmia</p>
<p><b>Frequency not reported</b>: QT interval prolongation</p>
<p><b>Postmarketing reports</b>: Ventricular arrhythmia, ventricular tachycardia, torsades de pointes, hemorrhage<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased WBC (less than 1 x 10[9]/L), platelet count (less than 50 x 10[9]/L), and hemoglobin (less than 8 g/dL) were reported in up to 4%, up to 4%, and 3% of patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased WBC, decreased platelet count, decreased hemoglobin</p>
<p><b>Uncommon</b> (0.1% to 1%): Leukopenia, neutropenia, thrombocythemia, eosinophilia, increased prothrombin time</p>
<p><b>Frequency not reported</b>: Granulocytopenia, reduction in prothrombin time</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia, agranulocytosis, prolonged prothrombin time, decreased WBC count, increased INR<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, hyperhidrosis, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria, dermatitis bullous, maculopapular rash, cellulitis, pustular rash (non-urticarial), stained fingernails</p>
<p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne, erysipelas, erythrasma<sup>[Ref]</sup></p><h3>Other</h3><p>Many reports of extended-release tablets in the stool occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened gastrointestinal transit times.  In several reports, tablet residues occurred in the context of diarrhea.</p>
<p></p>
<p>Colchicine toxicity has been reported with concomitant use of this drug and colchicine, especially in the elderly; some occurred in patients with renal dysfunction.  Death occurred in some such patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Infection, candidiasis, pyrexia/fever, asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Malaise, chest pain, chills, fatigue, thirst, abnormal albumin globulin ratio, body aches and pains, flushing, accidental injury, flu syndrome</p>
<p><b>Postmarketing reports</b>: Otitis media, extended-release tablets in the stool, colchicine toxicity<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>The incidence of insomnia was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.</p>
<p></p>
<p>Psychotic disorder, confusional state, depersonalization, depression, disorientation, manic behavior, hallucination, abnormal behavior, and/or abnormal dreams usually resolved after the drug was stopped.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anxiety, nervousness, screaming, depression, sleep disturbance</p>
<p><b>Frequency not reported</b>: Behavioral changes, nightmares, psychosis</p>
<p><b>Postmarketing reports</b>: Psychotic disorder, confusional state, depersonalization, disorientation, hallucination, depression, manic behavior, abnormal behavior, abnormal dreams<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increased alkaline phosphatase (greater than 5 x ULN) was reported in up to 2% of patients.</p>
<p></p>
<p>Hypoglycemia has been reported in patients receiving oral hypoglycemic agents or insulin.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase</p>
<p><b>Uncommon</b> (0.1% to 1%): Anorexia, decreased appetite, increased blood LDH</p>
<p><b>Postmarketing reports</b>: Hypoglycemia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, rhinitis, increased cough, pharyngitis, asthma</p>
<p><b>Uncommon</b> (0.1% to 1%): Epistaxis, pulmonary embolism</p>
<p><b>Frequency not reported</b>: Laryngismus<sup>[Ref]</sup></p><p>The incidence of dyspnea was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Photophobia</p>
<p><b>Very rare</b> (less than 0.01%): Uveitis</p>
<p><b>Frequency not reported</b>: Corneal opacities<sup>[Ref]</sup></p><p>Uveitis was reported primarily in patients treated with concomitant rifabutin; most cases were reversible.</p>
<p></p>
<p>A case of corneal opacities was reported in a patient with AIDS and Mycobacterium avium complex bacteremia.  The patient's ocular signs and symptoms resolved upon substitution with azithromycin.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Elevated BUN, elevated serum creatinine, increased blood urea, increased blood creatinine</p>
<p><b>Frequency not reported</b>: Acute renal failure</p>
<p><b>Postmarketing reports</b>: Interstitial nephritis, renal failure<sup>[Ref]</sup></p><p>Elevated BUN (greater than 50 mg/dL) was reported in less than 1% of patients.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Myalgia, muscle spasms, nuchal rigidity, musculoskeletal stiffness, arthralgia, back pain</p>
<p><b>Postmarketing reports</b>: Myopathy, rhabdomyolysis</p><p>In some cases of rhabdomyolysis, this drug was coadministered with statins, fibrates, colchicine, or allopurinol.</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Vaginal infection</p>
<p><b>Postmarketing reports</b>: Abnormal urine color (associated with hepatic failure), dysuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (0.01% to 0.1%): Leukocytoclastic vasculitis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_4">4. Karma P, Pukander J, Penttila M, et al "The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis." J Antimicrob Chemother 27 (1991): 83-90</p><p id="ref_5">5. Pijpers E, Vanrijswijk REN, Takxkohlen B, Schrey G "A clarithromycin-induced myasthenic syndrome." Clin Infect Dis 22 (1996): 175-6</p><p id="ref_6">6. Zuckerman JM, Kaye KM "The newer macrolides: azithromycin and clarithromycin." Infect Dis Clin North Am 9 (1995): 731-45</p><p id="ref_7">7. Anderson G, Esmonde T, Coles S, et al "A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia." J Antimicrob Chemother 27 (1991): 117-24</p><p id="ref_8">8. Nightingale SD, Koster FT, Mertz GJ, Loss SD "Clarithromycin-induced mania in two patients with AIDS." Clin Infect Dis 20 (1995): 1563-4</p><p id="ref_9">9. Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, Thomas PT, Hoffstein V, Bourbeau J, Macdonald GF, Mclellan PA, "Clarithromycin versus cefaclor in lower respiratory tract infections." Clin Invest Med 18 (1995): 131-8</p><p id="ref_10">10. Peters D, Clissold S "Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential." Drugs 44 (1992): 117-64</p><p id="ref_11">11. Hamedani P, Ali J, Hafeez S, et al "The safety and efficacy of clarithromycin in patients with legionella pneumonia." Chest 100 (1991): 1503-6</p><p id="ref_12">12. Straneo G, Scarpazza G "Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia." J Int Med Res 18 (1990): 164-70</p><p id="ref_13">13. Macfarlane JT, Prewitt J, Gard P, Guion A "Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections." Br J Gen Pract 46 (1996): 357-60</p><p id="ref_14">14. Dorrell L, Ellerton C, Cottrell DG, Snow MH "Toxicity of clarithromycin in the treatment of mycobacterium avium complex infection in a patient with AIDS." J Antimicrob Chemother 34 (1994): 605-6</p><p id="ref_15">15. Dautzenberg B, Piperno D, Diot P, Truffotpernot C, Chauvin JP "Clarithromycin in the treatment of mycobacterium avium lung infections in patients without AIDS." Chest 107 (1995): 1035-40</p><p id="ref_16">16. Guay D, Craft J "Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis." J Intern Med 231 (1992): 295-301</p><p id="ref_17">17. "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_18">18. Wood M "The tolerance and toxicity of clarithromycin." J Hosp Infect 19 (1991): 39-46</p><p id="ref_19">19. Hardy D, Guay D, Jones R "Clarithromycin, a unique macrolide." Diagn Microbiol Infect Dis 15 (1992): 39-53</p><p id="ref_20">20. Marchi E "Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis." Curr Med Res Opin 12 (1990): 19-24</p><p id="ref_21">21. Liviu L, Yair L, Yehuda S "Pancreatitis induced by clarithromycin." Ann Intern Med 125 (1996): 701</p><p id="ref_22">22. Fraschini F "Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis." J Int Med Res 18 (1990): 171-76</p><p id="ref_23">23. de Campora E, Camaioni A, Leonardi M, et al "Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections." Diagn Microbiol Infect Dis 15 (1992): s119-22</p><p id="ref_24">24. Baylor P, Williams K "Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy." Clin Infect Dis 29 (1999): 1350-1</p><p id="ref_25">25. Brown BA, Wallace RJ, Griffith DE, Girard W "Clarithromycin-induced hepatotoxicity." Clin Infect Dis 20 (1995): 1073-4</p><p id="ref_26">26. Shaheen N, Grimm IS "Fulminant hepatic failure associated with clarithromycin." Am J Gastroenterol 91 (1996): 394-5</p><p id="ref_27">27. Liviu L, Yair L "Pancreatitis induced by clarithromycin." Ann Intern Med 125 (1996): 701</p><p id="ref_28">28. Vangala R, Cernek PK "Hypersensitivity reaction to clarithromycin." Ann Pharmacother 30 (1996): 300</p><p id="ref_29">29. Lee KL, Jim MH, Tang SC, Tai YT "QT prolongation and Torsades de pointes associated with clarithromycin." Am J Med 104 (1998): 395-6</p><p id="ref_30">30. Kundu S, Williams SR, Nordt SP, Clark RF "Clarithromycin-induced ventricular tachycardia." Ann Emerg Med 30 (1997): 542-4</p><p id="ref_31">31. GomezGil E, Garcia F, Pintor L, Martinez JA, Mensa J, dePablo J "Clarithromycin-induced acute psychoses in peptic ulcer disease." Eur J Clin Microbiol Infect D 18 (1999): 70-1</p><p id="ref_32">32. Abouesh A, Hobbs WR "Clarithromycin-induced mania." Am J Psychiatry 155 (1998): 1626</p><p id="ref_33">33. Cone LA, Sneider RA, Nazemi R, Dietrich EJ "Mania due to clarithromycin therapy in a patient who was not infected with human immunodeficiency virus." Clin Infect Dis 22 (1996): 595-6</p><p id="ref_34">34. Mermelstein HT "Clarithromycin-induced delirium in a general hospital." Psychosomatics 39 (1998): 540-2</p><p id="ref_35">35. Geiderman JM "Central nervous system disturbances following clarithromycin ingestion." Clin Infect Dis 29 (1999): 464-5</p><p id="ref_36">36. "WHO system finds 13 drugs with AEs not in PDR, Martindale." F-D-C Reports -- "The Pink Sheet" 60 (1998): 16</p><p id="ref_37">37. Gavura SR, Nusinowitz S "Leukocytoclastic vasculitis associated with clarithromycin." Ann Pharmacother 32 (1998): 543-5</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Can I drink alcohol while taking clarithromycin?</li>
<li>What are the best antibiotics for pneumonia?</li>
<li>What is the best antibiotic to treat strep throat?</li>
<li>Can clarithromycin be used to treat UTI's?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about clarithromycin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>717 Reviews</li>
<li>Drug class: macrolides</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Clarithromycin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Biaxin, Biaxin XL</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Dental Abscess</li>
<li>Bacterial Endocarditis Prevention</li>
<li>Bronchitis</li>
<li>Follicular Lymphoma</li>
<li data-more-config-id="list-data-resources-conditions">... +18 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to clarithromycin: oral powder for reconstitution, oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most common side effects were abdominal pain/discomfort, diarrhea, nausea, vomiting, and dysgeusia/taste perversion.</p><p></p><p>In immunocompromised patients treated with higher doses of this drug (1 to 2 g/day), the most common side effects were nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, increased AST, and increased ALT.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia/taste perversion (up to 16%)</p><p><b>Common</b> (1% to 10%): Headache, dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Loss of consciousness, dyskinesia, somnolence, hearing impaired, tinnitus, tremor, vertigo</p><p><b>Frequency not reported</b>: New onset of symptoms of myasthenic syndrome, exacerbation of symptoms of myasthenia gravis, hearing disturbance, muzziness</p><p><b>Postmarketing reports</b>: Convulsions, ageusia, parosmia/smell perversion, anosmia, paresthesia, deafness, hyperkinesia<sup>[Ref]</sup></p><p>Deafness was reported mainly in elderly women and was usually reversible.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>The incidence of dry mouth was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.</p><p></p><p>Severity of pseudomembranous colitis has ranged from mild to life-threatening.</p><p></p><p>Tooth discoloration was usually reversible with professional dental cleaning after the drug was stopped.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 12.3%)</p><p><b>Common</b> (1% to 10%): Diarrhea, vomiting, abdominal pain/discomfort, dyspepsia/heartburn, flatulence, oral candidiasis/moniliasis, constipation</p><p><b>Uncommon</b> (0.1% to 1%): Glossitis, stomatitis, esophagitis, gastroesophageal reflux disease, gastritis, proctalgia, abdominal distension, dry mouth, eructation, gastroenteritis, gastrointestinal hemorrhage, bleeding gums, bloodstained stools</p><p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis), pancreatitis</p><p><b>Postmarketing reports</b>: Acute pancreatitis, tongue discoloration, tooth discoloration, pseudomembranous colitis, enteritis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site phlebitis</p><p><b>Common</b> (1% to 10%): Injection site pain, injection site inflammation, tenderness at site of administration</p><p><b>Frequency not reported</b>: Vessel puncture site pain</p><p>These side effects are specific to the IV formulation.</p><h3>Hepatic</h3><p>Elevated AST (greater than 5 times the upper limit of normal [5 x ULN]) and ALT (greater than 5 x ULN) were reported in up to 4% and up to 3% of patients, respectively.</p><p></p><p>Hepatic dysfunction (sometimes severe and usually reversible), including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice have been reported.  In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases (e.g., preexisting liver disease) and/or concomitant medications (e.g., hepatotoxic agents).</p><p></p><p>Drug-induced hepatotoxicity was rare and typically associated with higher doses (1 to 2 g/day) and high serum drug levels.  The enzyme elevation pattern was usually cholestatic with minimal elevations of AST and ALT.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT, abnormal liver function test</p><p><b>Uncommon</b> (0.1% to 1%): Cholestasis, hepatitis (symptoms included anorexia, jaundice, dark urine, pruritus, tender abdomen), increased blood bilirubin, elevated GGT, elevated direct bilirubin, hepatic dysfunction (including increased liver enzymes), hepatitis and cholestasis with or without jaundice</p><p><b>Frequency not reported</b>: Hepatocellular and/or cholestatic hepatitis (with or without jaundice), drug-induced hepatotoxicity, fulminant hepatic failure</p><p><b>Postmarketing reports</b>: Hepatic failure, hepatocellular jaundice, adverse reactions related to hepatic dysfunction, abnormal hepatic function, liver abnormalities<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactoid reaction</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity, allergic reactions</p><p><b>Postmarketing reports</b>: Anaphylactic reaction, angioedema<sup>[Ref]</sup></p><p>Allergic reactions have ranged from urticaria and mild skin eruptions to rare cases of anaphylaxis.</p><p></p><p>A 92-year-old female admitted for heart failure and a right upper lobe infiltrate was started on clarithromycin 500 mg.  The following day, this drug was discontinued and IV antibiotics were initiated due to persisting fever.  She received only 1 dose of this drug.  On day 6 of the hospitalization, the patient was afebrile, IV antibiotics were stopped, and this drug was again started.  Two hours after the dose, the patient developed swelling in her lips, jaw, tongue, mouth, and face.  The patient was given diphenhydramine and the clarithromycin was discontinued.  She was discharged the following day.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Vasodilation, phlebitis</p><p><b>Uncommon</b> (0.1% to 1%): ECG QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations</p><p><b>Rare</b> (0.01% to 0.1%): Arrhythmia</p><p><b>Frequency not reported</b>: QT interval prolongation</p><p><b>Postmarketing reports</b>: Ventricular arrhythmia, ventricular tachycardia, torsades de pointes, hemorrhage<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased WBC (less than 1 x 10[9]/L), platelet count (less than 50 x 10[9]/L), and hemoglobin (less than 8 g/dL) were reported in up to 4%, up to 4%, and 3% of patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased WBC, decreased platelet count, decreased hemoglobin</p><p><b>Uncommon</b> (0.1% to 1%): Leukopenia, neutropenia, thrombocythemia, eosinophilia, increased prothrombin time</p><p><b>Frequency not reported</b>: Granulocytopenia, reduction in prothrombin time</p><p><b>Postmarketing reports</b>: Thrombocytopenia, agranulocytosis, prolonged prothrombin time, decreased WBC count, increased INR<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, hyperhidrosis, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria, dermatitis bullous, maculopapular rash, cellulitis, pustular rash (non-urticarial), stained fingernails</p><p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne, erysipelas, erythrasma<sup>[Ref]</sup></p><h3>Other</h3><p>Many reports of extended-release tablets in the stool occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened gastrointestinal transit times.  In several reports, tablet residues occurred in the context of diarrhea.</p><p></p><p>Colchicine toxicity has been reported with concomitant use of this drug and colchicine, especially in the elderly; some occurred in patients with renal dysfunction.  Death occurred in some such patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Infection, candidiasis, pyrexia/fever, asthenia</p><p><b>Uncommon</b> (0.1% to 1%): Malaise, chest pain, chills, fatigue, thirst, abnormal albumin globulin ratio, body aches and pains, flushing, accidental injury, flu syndrome</p><p><b>Postmarketing reports</b>: Otitis media, extended-release tablets in the stool, colchicine toxicity<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>The incidence of insomnia was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.</p><p></p><p>Psychotic disorder, confusional state, depersonalization, depression, disorientation, manic behavior, hallucination, abnormal behavior, and/or abnormal dreams usually resolved after the drug was stopped.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Anxiety, nervousness, screaming, depression, sleep disturbance</p><p><b>Frequency not reported</b>: Behavioral changes, nightmares, psychosis</p><p><b>Postmarketing reports</b>: Psychotic disorder, confusional state, depersonalization, disorientation, hallucination, depression, manic behavior, abnormal behavior, abnormal dreams<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increased alkaline phosphatase (greater than 5 x ULN) was reported in up to 2% of patients.</p><p></p><p>Hypoglycemia has been reported in patients receiving oral hypoglycemic agents or insulin.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase</p><p><b>Uncommon</b> (0.1% to 1%): Anorexia, decreased appetite, increased blood LDH</p><p><b>Postmarketing reports</b>: Hypoglycemia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, rhinitis, increased cough, pharyngitis, asthma</p><p><b>Uncommon</b> (0.1% to 1%): Epistaxis, pulmonary embolism</p><p><b>Frequency not reported</b>: Laryngismus<sup>[Ref]</sup></p><p>The incidence of dyspnea was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis</p><p><b>Uncommon</b> (0.1% to 1%): Photophobia</p><p><b>Very rare</b> (less than 0.01%): Uveitis</p><p><b>Frequency not reported</b>: Corneal opacities<sup>[Ref]</sup></p><p>Uveitis was reported primarily in patients treated with concomitant rifabutin; most cases were reversible.</p><p></p><p>A case of corneal opacities was reported in a patient with AIDS and Mycobacterium avium complex bacteremia.  The patient's ocular signs and symptoms resolved upon substitution with azithromycin.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Elevated BUN, elevated serum creatinine, increased blood urea, increased blood creatinine</p><p><b>Frequency not reported</b>: Acute renal failure</p><p><b>Postmarketing reports</b>: Interstitial nephritis, renal failure<sup>[Ref]</sup></p><p>Elevated BUN (greater than 50 mg/dL) was reported in less than 1% of patients.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Myalgia, muscle spasms, nuchal rigidity, musculoskeletal stiffness, arthralgia, back pain</p><p><b>Postmarketing reports</b>: Myopathy, rhabdomyolysis</p><p>In some cases of rhabdomyolysis, this drug was coadministered with statins, fibrates, colchicine, or allopurinol.</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Vaginal infection</p><p><b>Postmarketing reports</b>: Abnormal urine color (associated with hepatic failure), dysuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (0.01% to 0.1%): Leukocytoclastic vasculitis<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_4">4. Karma P, Pukander J, Penttila M, et al "The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis." J Antimicrob Chemother 27 (1991): 83-90</p><p id="ref_5">5. Pijpers E, Vanrijswijk REN, Takxkohlen B, Schrey G "A clarithromycin-induced myasthenic syndrome." Clin Infect Dis 22 (1996): 175-6</p><p id="ref_6">6. Zuckerman JM, Kaye KM "The newer macrolides: azithromycin and clarithromycin." Infect Dis Clin North Am 9 (1995): 731-45</p><p id="ref_7">7. Anderson G, Esmonde T, Coles S, et al "A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia." J Antimicrob Chemother 27 (1991): 117-24</p><p id="ref_8">8. Nightingale SD, Koster FT, Mertz GJ, Loss SD "Clarithromycin-induced mania in two patients with AIDS." Clin Infect Dis 20 (1995): 1563-4</p><p id="ref_9">9. Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, Thomas PT, Hoffstein V, Bourbeau J, Macdonald GF, Mclellan PA, "Clarithromycin versus cefaclor in lower respiratory tract infections." Clin Invest Med 18 (1995): 131-8</p><p id="ref_10">10. Peters D, Clissold S "Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential." Drugs 44 (1992): 117-64</p><p id="ref_11">11. Hamedani P, Ali J, Hafeez S, et al "The safety and efficacy of clarithromycin in patients with legionella pneumonia." Chest 100 (1991): 1503-6</p><p id="ref_12">12. Straneo G, Scarpazza G "Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia." J Int Med Res 18 (1990): 164-70</p><p id="ref_13">13. Macfarlane JT, Prewitt J, Gard P, Guion A "Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections." Br J Gen Pract 46 (1996): 357-60</p><p id="ref_14">14. Dorrell L, Ellerton C, Cottrell DG, Snow MH "Toxicity of clarithromycin in the treatment of mycobacterium avium complex infection in a patient with AIDS." J Antimicrob Chemother 34 (1994): 605-6</p><p id="ref_15">15. Dautzenberg B, Piperno D, Diot P, Truffotpernot C, Chauvin JP "Clarithromycin in the treatment of mycobacterium avium lung infections in patients without AIDS." Chest 107 (1995): 1035-40</p><p id="ref_16">16. Guay D, Craft J "Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis." J Intern Med 231 (1992): 295-301</p><p id="ref_17">17. "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_18">18. Wood M "The tolerance and toxicity of clarithromycin." J Hosp Infect 19 (1991): 39-46</p><p id="ref_19">19. Hardy D, Guay D, Jones R "Clarithromycin, a unique macrolide." Diagn Microbiol Infect Dis 15 (1992): 39-53</p><p id="ref_20">20. Marchi E "Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis." Curr Med Res Opin 12 (1990): 19-24</p><p id="ref_21">21. Liviu L, Yair L, Yehuda S "Pancreatitis induced by clarithromycin." Ann Intern Med 125 (1996): 701</p><p id="ref_22">22. Fraschini F "Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis." J Int Med Res 18 (1990): 171-76</p><p id="ref_23">23. de Campora E, Camaioni A, Leonardi M, et al "Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections." Diagn Microbiol Infect Dis 15 (1992): s119-22</p><p id="ref_24">24. Baylor P, Williams K "Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy." Clin Infect Dis 29 (1999): 1350-1</p><p id="ref_25">25. Brown BA, Wallace RJ, Griffith DE, Girard W "Clarithromycin-induced hepatotoxicity." Clin Infect Dis 20 (1995): 1073-4</p><p id="ref_26">26. Shaheen N, Grimm IS "Fulminant hepatic failure associated with clarithromycin." Am J Gastroenterol 91 (1996): 394-5</p><p id="ref_27">27. Liviu L, Yair L "Pancreatitis induced by clarithromycin." Ann Intern Med 125 (1996): 701</p><p id="ref_28">28. Vangala R, Cernek PK "Hypersensitivity reaction to clarithromycin." Ann Pharmacother 30 (1996): 300</p><p id="ref_29">29. Lee KL, Jim MH, Tang SC, Tai YT "QT prolongation and Torsades de pointes associated with clarithromycin." Am J Med 104 (1998): 395-6</p><p id="ref_30">30. Kundu S, Williams SR, Nordt SP, Clark RF "Clarithromycin-induced ventricular tachycardia." Ann Emerg Med 30 (1997): 542-4</p><p id="ref_31">31. GomezGil E, Garcia F, Pintor L, Martinez JA, Mensa J, dePablo J "Clarithromycin-induced acute psychoses in peptic ulcer disease." Eur J Clin Microbiol Infect D 18 (1999): 70-1</p><p id="ref_32">32. Abouesh A, Hobbs WR "Clarithromycin-induced mania." Am J Psychiatry 155 (1998): 1626</p><p id="ref_33">33. Cone LA, Sneider RA, Nazemi R, Dietrich EJ "Mania due to clarithromycin therapy in a patient who was not infected with human immunodeficiency virus." Clin Infect Dis 22 (1996): 595-6</p><p id="ref_34">34. Mermelstein HT "Clarithromycin-induced delirium in a general hospital." Psychosomatics 39 (1998): 540-2</p><p id="ref_35">35. Geiderman JM "Central nervous system disturbances following clarithromycin ingestion." Clin Infect Dis 29 (1999): 464-5</p><p id="ref_36">36. "WHO system finds 13 drugs with AEs not in PDR, Martindale." F-D-C Reports -- "The Pink Sheet" 60 (1998): 16</p><p id="ref_37">37. Gavura SR, Nusinowitz S "Leukocytoclastic vasculitis associated with clarithromycin." Ann Pharmacother 32 (1998): 543-5</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Can I drink alcohol while taking clarithromycin?</li>
<li>What are the best antibiotics for pneumonia?</li>
<li>What is the best antibiotic to treat strep throat?</li>
<li>Can clarithromycin be used to treat UTI's?</li>
</ul><h2>More about clarithromycin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>717 Reviews</li>
<li>Drug class: macrolides</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Clarithromycin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Dental Abscess</li>
<li>Bacterial Endocarditis Prevention</li>
<li>Bronchitis</li>
<li>Follicular Lymphoma</li>
<li data-more-config-id="list-data-resources-conditions">... +18 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>